Sarah Denny

At the intersection of biophysics and genomics. Leading the Molecular Engineering team at Scribe Therapeutics @scribetx

[Sarah Denny @SarahSeq]

@markwbudde Come visit Scribe?

[Sarah Denny @SarahSeq]

Excited to join this @SFBusinessTimes panel to share my career path from academia to industry. It’s an honor to represent @scribetx as one of #SFBTwomenwholead in the life sciences.

[Scribe Therapeutics @scribetx]

This Friday, Scribe’s Director of #MolecularEngineering @SarahSeq will join a ‘Rising Stars’ panel moderated by @rleuty_biotech for @SFBusinessTimes' 'Women Who Lead in Life Sciences' panel. For more about #SFBTwomenwholead, visit: https://t.co/ND0M4Ze1kg
#CRISPRbyDesign #IWD2023

[Scribe Therapeutics @scribetx]

Announcing our latest partnership: We’re proud that @Sanofi selected our CRISPR by Design™ platform and genome editing XE technology to enable the development of novel natural killer cell therapies for cancer. https://t.co/wF8TX3qKQq

#CRISPR #CRISPRbyDesign #Oncology

[Sarah Denny @SarahSeq]

Looking forward to discussing the profound impact of #ArtificialIntelligence on the drug development world, including in our work at @scribetx, with my fellow #WomenInBio. Thank you @SFWomenInBio and @Illumina for hosting! More at https://t.co/dDF8uCTmDt

#CRISPR #WomenInSTEM

[Scribe Therapeutics @scribetx]

Tomorrow is the last day to register for Wednesday’s @SFWomenInBio panel on the impact of artificial intelligence on drug discovery, featuring our Head of Molecular Engineering @SarahSeq! Grab your ticket now at https://t.co/f7xWGYMzaC

#WomenInBio @WomenInBio #CRISPR #AI

[Mark Budde 🦕🏆 @markwbudde]

Primordium is now offering everyone the chance to sample our full-plasmid sequencing service for FREE - never use Sanger sequencing again! Please retweet this message and we'll DM you a coupon to sequence 5 ENTIRE PLASMIDS 100% FREE, no CC or PO needed. https://t.co/U4WeR2ftjL 5/

[Steve L. Bonilla @Steve_Bonilla]

Happy to share my last grad school paper published today @PNASNews https://t.co/QKhRuGv65d in collaboration with @SarahSeq and @WJGreenleaf lab. Using high-throughput biochemistry to understand RNA 3D structure from the behavior of small recurring modular 3D building blocks.

[Scribe Therapeutics @scribetx]

1/ We’re excited to announce the completion of our $100M Series B financing to further develop our ”CRISPR by Design” platform and pipeline of #CRISPR-based in vivo genetic medicines that treat the underlying cause of disease. https://t.co/g34FRhnQYg

[Sarah Denny @SarahSeq]

Excited to have you join Scribe, Jason!

[Jason Fernandes @jdf_ev]

So I'm excited to announce I'll be joining the team @scribetx - Scribe is dedicated to engineering the future of gene therapy & part of that mission will involve taking/improving the tools evolution uses to innovate in order to build the best platform for genetic medicine.

[Sarah Denny @SarahSeq]

@acolavin I’ve spread the word to my lab mates!

[Sarah Denny @SarahSeq]

Excited to be part of this team working to cure the underlying cause of genetic diseases! https://t.co/f1usxxr0jA

[Scribe Therapeutics @scribetx]

1/ We are excited to take the wraps off Scribe Therapeutics - a molecular engineering company focused on building best-in-class in vivo therapies to permanently treat the underlying cause of disease. Read our launch press release: https://t.co/pj54vbtJaV